PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Evaluating the Antihyperalgesic Potential of Sildenafil-Metformin Combination and Its Impact on Biochemical Markers in Alloxan-Induced Diabetic Neuropathy in Rats
Version 1
: Received: 29 March 2024 / Approved: 29 March 2024 / Online: 29 March 2024 (13:45:41 CET)
How to cite:
Pușcașu, C.; Zbârcea, C.E.; Ungurianu, A.; Ștefănescu, E.; Chiriță, C.; Blebea, N.M.; Negreș, S. Evaluating the Antihyperalgesic Potential of Sildenafil-Metformin Combination and Its Impact on Biochemical Markers in Alloxan-Induced Diabetic Neuropathy in Rats. Preprints2024, 2024031853. https://doi.org/10.20944/preprints202403.1853.v1
Pușcașu, C.; Zbârcea, C.E.; Ungurianu, A.; Ștefănescu, E.; Chiriță, C.; Blebea, N.M.; Negreș, S. Evaluating the Antihyperalgesic Potential of Sildenafil-Metformin Combination and Its Impact on Biochemical Markers in Alloxan-Induced Diabetic Neuropathy in Rats. Preprints 2024, 2024031853. https://doi.org/10.20944/preprints202403.1853.v1
Pușcașu, C.; Zbârcea, C.E.; Ungurianu, A.; Ștefănescu, E.; Chiriță, C.; Blebea, N.M.; Negreș, S. Evaluating the Antihyperalgesic Potential of Sildenafil-Metformin Combination and Its Impact on Biochemical Markers in Alloxan-Induced Diabetic Neuropathy in Rats. Preprints2024, 2024031853. https://doi.org/10.20944/preprints202403.1853.v1
APA Style
Pușcașu, C., Zbârcea, C.E., Ungurianu, A., Ștefănescu, E., Chiriță, C., Blebea, N.M., & Negreș, S. (2024). Evaluating the Antihyperalgesic Potential of Sildenafil-Metformin Combination and Its Impact on Biochemical Markers in Alloxan-Induced Diabetic Neuropathy in Rats. Preprints. https://doi.org/10.20944/preprints202403.1853.v1
Chicago/Turabian Style
Pușcașu, C., Nicoleta Mirela Blebea and Simona Negreș. 2024 "Evaluating the Antihyperalgesic Potential of Sildenafil-Metformin Combination and Its Impact on Biochemical Markers in Alloxan-Induced Diabetic Neuropathy in Rats" Preprints. https://doi.org/10.20944/preprints202403.1853.v1
Abstract
(1) Background: Globally, about 600 million people are afflicted with diabetes, and one of its most prevalent complications is neuropathy, a debilitating condition. At present, the exploration of novel therapies for alleviating diabetic neuropathy-associated pain is genuinely captivating, considering that current therapeutic options are characterized by poor efficacy and significant risk of side effects. In the current research, we evaluated the antihyperalgesic effect of sildenafil (phosphodiesterase-5 inhibitor) – metformin (antihyperglycemic agent) combination and its impact on biochemical markers in alloxan-induced diabetic neuropathy in rats; (2) Methods: The study comprised a cohort of 70 diabetic rats and 10 non-diabetic rats which were submitted to hot, cold, and tactile stimulus tests. Morover, we investigated the influence of this combination on TNF-α, IL-6 nitrites and thiols levels in brain and liver tissues; (3) Results: The results demonstrated that all sildenafil-metformin combinations decreased the pain sensitivity in von Frey test, Hot-plate test and Cold-plate test. Furthermore, alterations in nitrites and thiols concentrations and pro-inflammatory cytokines (specifically TNF-α and IL-6) were noted following a 15-day regimen of various sildenafil-metformin combinations. (4) Conclusions: The combination of sildenafil and metformin has a synergistic effect in alleviating pain in alloxan-induced diabetic neuropathy rats. Additionally, the combination effectively decreased inflammation, inhibited the rise in NOS activity, and provided protection against glutathione depletion.
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
*
,
